Sermorelin supports hormone signaling and long-term optimization
Deviating from the studied dosing schedule introduces unknowns about efficacy and side effect profiles
Beyond their established role in T2D, GLP-1RAs are under investigation for potential therapeutic applications in additional clinical domains: non-alcoholic fatty liver disease (NAFLD) [22], neurodegenerative conditions [23], and addiction reduction(including smoking, alcohol use disorder, and cocaine use disorder, putatively via mechanisms analogous to those underlying appetite suppression) [23]
Compared to other antidiabetic drugs, including subcutaneously administrated GLP-1R agonists, oral semaglutide is associated with significant improvements in HbA1c levels and body weight of patients with T2D and is either non-inferior or superior in effect
What I'm saying is, is working, but which one is the needle, needle mover, or is it an attrition of all of them